Initially, the FIGHT-202 study demonstrated for the first time that a selective, oral FGFR inhibitor resulted in an objective response in previously treated CCA patients with detectable FGFR2 gene rearrangements [41], a finding leading to the approval of pemigatinib monotherapy for the treatment of adults with FGFR2 fusion-positive CCA that have progressed after at least one prior line of systemic therapy. The gene discussed is FGFR2; the disease is cholangiocarcinoma.